In The Know-April 2026

April 2026
Pdf Summary
This April 2026 “Ed’s List” highlights major gynecologic oncology papers spanning ovarian, endometrial, cervical, and hereditary cancer care, with several studies focused on treatment outcomes, biomarkers, survivorship, and patient decision-making.<br /><br />Key ovarian cancer findings include: maintenance olaparib plus bevacizumab in PAOLA-1 did not meaningfully worsen quality of life; relacorilant plus nab-paclitaxel improved overall survival in platinum-resistant ovarian cancer; and pembrolizumab plus lenvatinib showed promising activity in recurrent gynecologic clear cell carcinoma. Multiple biomarker studies reported potential clinical tools, including a validated blood DNA methylation signature (PLAT-M8) for prognosis after relapse, a urinary three-metabolite risk model, circulating tumor cells predicting poor outcome in high-grade serous ovarian cancer, and whole-body diffusion MRI helping predict resectability and survival after neoadjuvant chemotherapy. Germline testing in Chinese epithelial ovarian cancer patients found over 25% carried homologous recombination–related variants.<br /><br />Surgical outcome papers raised caution: intrauterine manipulator use during minimally invasive hysterectomy for endometrial cancer may be linked to worse disease-free survival, and minimally invasive surgery for early ovarian cancer was associated with more capsule rupture. In advanced tubo-ovarian cancer, ileocecal and small bowel involvement predicted inferior survival despite complete cytoreduction.<br /><br />Several studies addressed prevention and survivorship. Five-year follow-up from the TUBA trial found salpingectomy with delayed oophorectomy preserved menopause-related quality of life compared with immediate oophorectomy. A large Women’s Health Initiative analysis linked high residential radon exposure to increased ovarian cancer incidence and mortality. Surveys showed clinicians generally support hormonal therapy after cervical chemoradiation but implementation remains inconsistent. Patient preference studies showed women at hereditary ovarian cancer risk strongly value cancer risk reduction, while also weighing menopause and cardiovascular/bone risks.<br /><br />Additional work mapped immune and stromal landscapes in rare ovarian tumors, identified BRCA-deficient high-grade serous tumor features linked to survival, and suggested cervical cancer chemoradiation may create actionable immune resistance pathways.
Keywords
gynecologic oncology
ovarian cancer
endometrial cancer
cervical cancer
hereditary cancer
biomarkers
maintenance olaparib
relacorilant
salpingectomy
quality of life